Galderma drug is first FDA-approved facial erythema of rosacea treatment

Switzerland-headquartered Galderma Laboratories says that the US Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older.

Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in US pharmacies September 2013.

“Facial redness is the most common symptom of rosacea but, until now, physicians have been without prescription treatment options to specifically address this patient need,” said Mark Jackson, Clinical Professor of Medicine at the University of Louisville, dermatologist and a principal investigator for the Phase III studies of Mirvaso, adding: “The FDA approval of Mirvaso marks a turning point in rosacea treatment: we are now able to provide patients who deal with the daily frustrations caused by the redness of rosacea with an effective therapy.”